Trials / Completed
CompletedNCT01532128
Effect of BIA 9-1067 on Rasagiline Pharmacokinetics
Effect of BIA 9-1067 on Rasagiline Pharmacokinetics in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Bial - Portela C S.A. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the effect of BIA 9-1067 on rasagiline pharmacokinetics in healthy subjects.
Detailed description
Single-centre, open-label, randomised, three-way crossover study consisting of 3 single-dose periods separated by a washout of 14 days or more
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rasagiline | 1 mg rasagiline (single-dose) |
| DRUG | BIA 9-1067 | 50 mg BIA 9-1067 (single-dose) |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-02-01
- Completion
- 2010-07-01
- First posted
- 2012-02-14
- Last updated
- 2015-08-20
- Results posted
- 2015-08-20
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01532128. Inclusion in this directory is not an endorsement.